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Background: Brain metastases (BM) and leptomeningeal disease (LMD) are uncommon in epithelial ovarian cancer
(EOC). We investigate the outcomes of modern radiation therapy (RT) as a primary treatment modality in patients
with EOC BM and LMD.
Methods: We evaluated 60 patients with EOC treated at our institution from 1996 to 2010 who developed BM. All
information was obtained from chart review.
Results: At EOC diagnosis, median age was 56.1 years and 88% of patients were stage III-IV. At time of BM
diagnosis, 46.7% of patients had 1 BM, 16.7% had two to three, 26.7% had four or more, and 10% had LMD. Median
follow-up after BM was 9.3 months (range, 0.3-82.3). All patients received RT, and 37% had surgical resection. LMD
occurred in the primary or recurrent setting in 12 patients (20%), 9 of whom received RT. Median overall survival
(OS) after BM was 9.7 months for all patients (95% CI 5.9–13.5), and 16.1 months (95% CI 3.8-28.3) in patients with
one BM. On multivariate analysis, Karnofsky performance status less than 70 (hazard ratio [HR] 2.86, p = 0.018), four
or more BM (HR 3.18, p = 0.05), LMD (HR 8.22, p = 0.013), and uncontrolled primary tumor (HR 2.84, p = 0.008) were
significantly associated with inferior OS. Use of surgery was not significant (p = 0.31). Median central nervous
system freedom from progression (CNS-FFP) in 47 patients with follow-up was 18.5 months (95% CI, 9.3–27.9). Only
four or more BM (HR 2.56, p = 0.04) was significantly associated with poorer CNS-FFP.
Conclusions: Based on our results, RT appears to be an effective treatment modality for brain metastases from EOC
and should be routinely offered. Karnofsky performance status less than 70, four or more BM, LMD, and
uncontrolled primary tumor predict for worse survival after RT for EOC BM. Whether RT is superior to surgery or
chemotherapy for EOC BM remains to be seen in a larger cohort.
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Epithelial ovarian cancer (EOC) accounts for 3% of cancers
among women, but is the fifth leading cause of cancer
death in women and the leading cause of gynecologic can-
cer death [1]. The predominant form of relapse after pri-
mary surgery and chemotherapy for EOC is in the
abdomen and pelvis [2]. Central nervous system (CNS) and
brain metastases (BM) in these patients are a rare occur-
rence, with reported incidence of 0.29-11.6% [3-9], but may* Correspondence: teckies@mskcc.org
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reproduction in any medium, provided the orbe increasing in incidence as extracranial disease is better
controlled with improved surgical and chemotherapeutic
options [9-11].
The therapeutic approach to patients with BM from
EOC is challenging due to the small numbers of cases
and short follow-up periods available in other series
[3-10,12]. No studies investigate the impact of modern
radiation therapy (RT) as a primary treatment modality in
these patients. Treatments vary widely, including best sup-
portive care, chemotherapy, steroids, whole brain radi-
ation therapy (WBRT), surgical resection, and stereotactic
radiosurgery (SRS). Median survival in existing studies of
EOC with BM has generally been poor, on the order ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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18–33 months in selected patients treated with multimodality
therapy that combines surgery, radiation therapy, and sys-
temic chemotherapy [3,5,13,14]. Prior studies of BM in
advanced malignancies and in small series of EOC have
found performance status, age, primary tumor control,
extracranial metastases, and treatment modality for BM to
be predictors of survival after BM [4,11,12,15,16]. Lepto-
meningeal disease (LMD) is regarded as a factor for poor
prognosis in other metastatic cancers [17-19] and has been
observed with increasing incidence in advanced malignan-
cies, especially in the era of magnetic resonance imaging
(MRI) [18]. However, LMD is still rarely reported in EOC.
We reviewed our institution’s experience using modern
RT, with or without craniotomy, to treat patients with BM
and LMD from EOC. We also identify predictors of sur-
vival after RT in this patient population.
Methods
This study was approved by the Institutional Review
Board, who also approved a waiver of informed consent.
Our institution’s gynecology database was searched for
patients with EOC who developed BM and received RT.
We identified 60 patients who were diagnosed between
October 1996 and April 2010. We performed a retrospect-
ive chart review to obtain demographic data, details of ini-
tial EOC diagnosis and treatment, Karnofsky Performance
Status (KPS), stage, grade, date of BM diagnosis, interval
to BM, site and number of BM, treatment type for BM,
systemic disease at BM diagnosis, follow-up and response
to treatment, date of CNS relapse or recurrence, time
interval to relapse or recurrence after initial BM, and date
of death or last follow-up. For two patients, the date of
death could not be determined. These patients were
censored at date of last follow-up. All BM, including
LMD, were diagnosed by imaging, most commonly MRI.
Overall survival (OS) was calculated as the time from
initial EOC or BM diagnosis to date of death or last
follow-up. CNS freedom from progression (CNS-FFP)
after BM was calculated from date of BM diagnosis to date
of CNS recurrence or last follow-up imaging. Patients
without follow-up imaging after BM treatment were
excluded from the CNS-FFP analysis. Survival rates were
determined using the Kaplan-Meier method, and survival
curves were compared using the log-rank test. Univariate
(UVA) and multivariate (MVA) survival analyses were
performed using a Cox proportional hazards model on OS
and CNS-FFP. Variables with p value ≤0.05 by UVA were
considered for the MVA, and forward procedure was used
to build the final model. A p value ≤0.05 was considered
significant for all analyses. All statistical analysis was
accomplished with the SPSS software package, version 19
(IBM, Armonk, NY).Results
Clinical characteristics
Patient characteristics at the time of initial BM diagnosis
are listed in Table 1. Median age at diagnosis of EOC
was 56.1 years (range, 31.2-79.0). Stage distribution [20]
at original diagnosis of EOC was 3 patients with stage I
(5%), 4 with stage II (6.7%), 40 with stage III (66.7%), and
13 with stage IV (21.7%). Histologic grade at diagnosis
was 2 patients with grade 1 (3%), 7 with grade 2 (12%), 49
with grade 3 (82%), and 2 unknown (3%). Tumor histology
was distributed as follows: 42 (70%) papillary serous, 8
(13%) endometrioid, 3 (5%) adenocarcinoma not other-
wise specified, 2 (3%) mixed carcinoma, and 1 each of
mixed adenocarcinoma, clear cell carcinoma, mucinous
adenocarcinoma, small cell carcinoma, and cystic ovarian
carcinoma.
Median follow-up from BM diagnosis for all 60 patients
was 9.3 months (range, 0.3-82.3). Median follow-up from
BM diagnosis for the six patients alive at analysis was
27.1 months (range, 0.7-82.2).
Initial treatment of brain metastases
Treatments for initial BM are shown in Figure 1. RT was
the sole treatment in 38 patients. Twenty-two patients
were also treated with surgical resection for initial BM:
16 had a single BM, three had 2–3 BM, and three had
four or more BM. In the six patients who underwent
craniotomy and had multiple BM, four patients had only
the one most symptomatic lesion removed, and two
patients who presented with two lesions had both com-
pletely resected. Median WBRT dose was 3000 cGy (range,
600 cGy-4400 cGy). Median SRS dose was 2100 cGy
(range, 1400–2200 cGy). Thirty-six patients (60%) had at
least one cycle of systemic chemotherapy following RT ±
surgery. After brain metastasis, ovarian cancers were
treated with vastly heterogenous systemic regimens: we
counted 18 unique regimens, and 19 patients received two
or more lines of chemotherapy. The most common com-
bination regimens were carboplatin and paclitaxel, followed
by gemcitabine and carboplatin or cisplatin. The most com-
mon single-agent regimens were paclitaxel, gemcitabine,
carboplatin, and liposomal doxorubicin. Patients with a
KPS ≥70 were more likely than patients with KPS <70 to
receive systemic therapy following local treatment of brain
disease (Chi square, p = 0.04). The remaining 40% of
patients either did not have information on chemotherapy
available, or did not receive chemotherapy. This group had
a median OS of 2.4 months after completing RT (range,
0.1-81.7).
Recurrences and salvage RT
Six patients were alive at time of analysis at a median
follow-up of 27.1 months after their initial BM (range,
0.7-82.2). Twenty-four patients developed recurrent or
Table 1 Clinical characteristics at time of initial brain
metastases
Characteristics N Range
Median age at BM Dx 56.1 years 31.2-79.0
Median interval from
EOC Dx to BM
3.4 years 0.08-26.8
Median interval from EOC Dx to BM
in stage I-II EOC
5.9 years 3.7-10.8
Median interval from EOC Dx to BM
in stage III-IV EOC
3.1 years 0.08-26.8
Number Percent
Age <65 52 87%
Age ≥65 8 13%
KPS <70 9 15%
KPS ≥70 42 70%
KPS unknown 9 15%





Location of initial BM:
Cerebral hemispheres 29 48%
Cerebellum 10 17%
Both 21 35%
Extracranial metastases at time of BM Dx:
None 10 17%
Limited and stable 11 18%
Limited and progressive 11 18%
Extensive and stable 11 18%
Extensive and progressive 16 27%
Unknown 1 2%




Chemotherapy in 3 months preceding BM Dx:
Yes 37 62%
No 23 38%
BM = brain metastasis; Dx = diagnosis; EOC = epithelial ovarian cancer;
KPS = Karnofsky Performance Score; LMD = leptomeningeal disease.
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7.3 months (range, 0.9-46.3). Thirteen patients received fur-
ther RT for their recurrence, including three treated with
conventional RT to the spine for leptomeningeal recur-
rence. Seven patients received further systemic chemother-
apy following diagnosis of their recurrent CNS disease.Leptomeningeal disease
LMD was diagnosed in 12 (20%) patients, either at time of
initial BM (n = 6) or as relapse of CNS disease (n = 6).
Median interval from initial BM diagnosis to secondary
LMD diagnosis was 7.2 months (range, 2.5-44.5). All but
one patient with LMD had a preceding or synchronous
BM. Treatments for LMD in the primary setting included
five WBRTand one partial brain radiation therapy (PBRT).
Treatments for relapsed LMD included WBRT (n = 2),
spine RT (2), systemic chemotherapy (1), and best support-
ive care (1). All patients who received RT and had follow-
up imaging had at least a partial response to therapy.
Survival
Median OS from EOC diagnosis was 67.1 months (95% CI,
54.9-69.4). Median OS after BM diagnosis was 9.7 months
(95% CI, 5.9-13.5) in all patients (Figure 2a), and 15.6 -
months in the 47 patients with follow-up (95% CI, 9.8-
21.3). Median OS from LMD diagnosis for the 6 patients
diagnosed with LMD at the time of initial BM was 3.6 -
months (95% CI, 0.69-15.8). Median CNS-FFP in the 47
patients with follow-up was 18.5 months (95% CI, 9.3-27.8).
In the 28 patients with a single BM, median OS after
BM was 16.1 months (95% CI, 3.8-28.3). Survival was no
different in patients who received surgical resection for a
single BM (log-rank, p = 0.32). Seven patients treated
with SRS alone had median OS of 60.2 months (95% CI,
9.7-not reached).
Univariate analysis of OS included the following poten-
tial factors, including those validated in the Recursive
Partitioning Analysis for brain metastases [15]: age at BM
diagnosis (<65 or ≥65), primary tumor pathologic stage
and grade, histology (papillary serous, endometrioid, or all
others), interval from EOC diagnosis to BM, KPS at BM
diagnosis (<70 or ≥70), primary tumor control status, ex-
tent of extracranial disease (limited or extensive), location
of BM, number of BM, presence of LMD, surgery as part
of treatment, and type of RT received (SRS, WBRT,
PBRT). The following factors were significantly associated
with OS on UVA: KPS less than 70 (vs ≥70, hazard ratio
[HR] 2.78, p = 0.008), four or more BM (vs. 1–3 BM; HR,
3.75; p < 0.001), LMD (vs. none; HR, 5.32; p = 0.001),
longer duration between EOC diagnosis and BM diagnosis
(HR, 1.01; p = 0.006), uncontrolled primary tumor (HR,
2.87; p = 0.001), extensive extracranial metastases (vs.
limited extracranial metastases; HR, 1.98; p = 0.036), BM
in both the cerebrum and cerebellum (vs either alone; HR,
2.49; p = 0.003), and use of SRS (vs. WBRT or PBRT; HR,
0.46; p = 0.03). The use of craniotomy had no effect on
OS (p = 0.31).
MVA (Table 2) identified KPS less than 70 (HR, 2.86;
p = 0.018), four or more BM (vs. 1 or 2–3 BM; HR, 3.18;
p = 0.053), LMD (vs. 1–4 BM; HR, 8.22; p = 0.013), and
uncontrolled primary tumor (HR, 2.84; p = 0.008) as risk
Figure 2 a. Overall survival for all patients using Kaplan-Meier method. b. Overall survival stratified by Karnofsky performance status. c.
Overall survival stratified by primary tumor control status. d. Overall survival stratified by number of brain metastases and leptomeningeal disease.
Figure 1 Treatments for initial brain metastases.
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KPS at BM diagnosis
≥70 (reference) 37/42 1.00
<70 9/9 2.86 0.018
Primary tumor controlled in abdomen
Yes (reference) 31/36 1.00
No 23/23 2.84 0.008
Number of BM or LMD
1 (reference) 24/28 1.00
2-3 8/10 1.51 0.490
4+ 16/16 3.18 0.053
LMD 6/6 8.22 0.013
Event = death. BM = brain metastasis; KPS = Karnofsky Performance Score;
LMD = leptomeningeal disease.
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for BM. Kaplan-Meier survival curves stratified by the
factors significant on MVA are shown in Figure 2b-d.
On UVA for CNS-FFP, the presence of four or more
BM was significant, with a negative association (HR, 4.09;
p = 0.006), when compared with 1–3 BM (Figure 3b). In
this analysis, 1 and 2–3 BM were combined since there
was no significant difference in CNS-FFP between the two
groups. Extensive extracranial disease was also significant
(vs. limited; HR, 2.95; p = 0.048). On MVA for CNS-FFP,Figure 3 a. Central nervous system (CNS) freedom from progression u
stratified by number of brain metastases.only four or more BM remained significant (HR, 2.56;
p = 0.04),
Discussion
Our series represents the largest in the published litera-
ture of RT for treatment of BM in EOC, with a total of
60 patients analyzed. We show that these patients can
be effectively treated with RT, with or without resection
of tumor, and that survival in these patients depends on
KPS, number of BM, presence of LMD, and presence of
uncontrolled primary tumor. We found no statistically
significant effects of age, tumor histology, grade, initial
disease stage, RT type, or use of surgical resection of
metastases on OS after diagnosis of BM.
While CNS metastases are rare in EOC, they appear to
be increasing in incidence as extracranial disease is bet-
ter controlled with modern chemotherapy. In our series,
patients with more advanced stage and grade comprise
the majority of patients who develop BM. The most com-
mon presentation was a single BM in 47% of patients.
Patients with single BM may be treated with surgery, SRS,
PBRT, and/or WBRT. In our series, seven patients treated
with SRS alone had a median OS of 60.2 months. While
this patient subset is small, the long survival is noteworthy
in a metastatic population, and likely indicates that these
patients were highly selected with good control of extracranial
disease and high KPS. Another smaller series has found
longer survival in well-selected patients treated with SRS
versus WBRT [21]. Patients treated with only WBRT tend
to have shorter median survival times [22], and this maysing Kaplan-Meier method. b. CNS freedom from progression
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BM.
The use of surgery and RT has been associated with
longer survival after BM in multiple smaller studies
[3-5,8,13,23-25]; however, our study found no significant
benefit to the use of surgery in 22 patients who received
postoperative RT. Pothuri et al. [13] published a series from
our institution of 14 patients treated with craniotomy and
postoperative RT, and found median survival of 18 months
and high rates of local control. Based on our current study
and those preceding, we recommend that patients with a
single BM, good KPS and limited extracranial disease be
considered for SRS or both craniotomy and RT as clinically
indicated. Ideally, single-modality SRS will be tested in
more patients with EOC and single BM to come to a better
understanding of the adequacy of SRS alone. In patients
with multiple BM, some data suggest that resection of mul-
tiple metastases may improve outcomes [26,27]; we could
not verify this finding in our population, as only two
patients fell into this category.
Our results add to the findings of the Radiation Therapy
Oncology Group (RTOG) Recursive Partitioning Analysis
(RPA) system [15] for BM in a variety of cancers, which
identified KPS ≥70, age <65 years, controlled primary car-
cinoma, and no extracranial systemic metastases as being
predictive of the longest survival after BM. We suspect
that age was not significant in our patients because the
majority of our patients fell under the 65-year-old cutoff
used by the RPA.
A large but older series of EOC BM includes 72 patients
from MD Anderson Cancer Center [4] treated heteroge-
neously since 1985, and none with upfront SRS or PBRT.
In that series, 8 (11%) patients received steroids alone, 35
(51%) WBRT alone, 8 (11%) surgery alone, and only 12
(17%) had both surgery and WBRT. Twenty-five patients
had a single BM, and 47 had multiple. The study does not
provide information on the use of salvage therapies for
CNS recurrence. Their patients had inferior outcomes to
those in our study; median OS was just 6.9 months in
patients with a single BM. On their univariate analysis of
potential prognostic factors, they did not include KPS or
primary tumor control, both of which are vitally important
risk factors for outcomes after BM, and are important for
determining treatment approach. Although comparing
outcomes between retrospective studies is challenging,
several possibilities may explain why our results are super-
ior to this series. First, almost half of our population had a
single BM, while two-thirds of the patients in the MD
Anderson series had multiple metastases. Second, none of
our patients were treated with steroids alone, a group that
had a significantly worse hazard ratio of death and
accounts for 11% of their population. Third, 37% of our
patients received multimodality therapy that included sur-
gery and RT, while only 17% of patients in their study weretreated in a similar fashion and represented the group with
the longest median survival. Surgical resection of a single
BM has been shown to improve survival in a randomized
clinical trial [28]; in this MD Anderson series, it does not
appear that all patients with single BM received surgery,
and none received SRS. Fourth, almost two-thirds of our
patients were treated with chemotherapy following treatment
of their BM, which may contribute to better outcomes (al-
though we were unable to include it in our Cox regression
analysis due to its vast heterogeneity). Fifth, it is not clear
that patients with relapse received salvage therapy, while
most of our patients received RT or chemotherapy at
CNS relapse. Lastly, patients treated at our institution are
followed closely and systematically for recurrence, and are
treated with early salvage therapy at time of relapse; it is un-
clear what the standard follow-up entailed in other studies.
Chen et al. [14] used the RTOG RPA classification sys-
tem in a population of 19 patients with EOC BM treated
with various approaches, and found that surgery was
associated with longer OS (33.7 months vs 7.4 months,
p = 0.006). However, only 9 patients underwent surgery,
and 8 of these also received adjuvant radiotherapy to the
brain, making the patient population too small to draw
definitive conclusions regarding the adequacy of surgery
alone for brain metastases in this population. Their UVA
found primary tumor control (p = 0.006) and number of
BM (p = 0.005) to be associated with OS, but the num-
ber of events was too small to perform a true multivari-
ate analysis. In our study, we also find that primary
tumor control and number of BM are important. Our
patient population differs in that we have three times as
many patients, and all are treated with RT. In addition,
our larger patient population likely includes patients that
are less highly selected than in the Chen study. In fact,
Chen et al. concede in their discussion section that the
relatively long overall survival of their study (median,
16.3 months) may be attributed to patient factors that are
pertinent to outcome but not accounted for in the study,
such as systemic therapy and institutional preference for
aggressive, multimodality therapy.
A recent multi-institutional retrospective study of 139
patients with brain metastases from various gynecologic
malignancies identified a group of 56 patients with ovar-
ian, fallopian tube, or peritoneal histology [11] (it is un-
clear how many of these patients had a true epithelial
ovarian carcinoma). While comparing this “ovarian” sub-
group to our patients is not entirely possible, given the
heterogeneity of their subgroup, the study has several note-
worthy findings. First, in the “ovarian” group, 80% received
RT, about half of which also received surgery and/or
chemotherapy for the BM. Second, median survival for the
56 patients was 12.5 months. Third, on a multivariate ana-
lysis across all gynecologic types, they found ovarian/tubal/
peritoneal disease origin was associated with improved survival
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sively when a BM is diagnosed.
In our series, 10 (20%) patients with BM also had LMD,
and 9/10 (90%) had a synchronous or prior BM. LMD is an
uncommon occurrence in advanced malignancy, estimated
to occur in 4-15% of solid tumors [19]. Previous series have
reported an incidence of synchronous or preexisting CNS
metastases in 28-75% of patients with LMD [17]. Clarke
et al. [18] reviewed a large series of LMD from our institu-
tion and reported that 70% of patients with LMD from
solid tumors had previous or current brain disease. In that
study, 59% of patients were treated with RT, 15% received
supportive therapy only, and the remainder had some form
of chemotherapy. Median OS after LMD was 2.3 months
for patients with solid tumors; there were 2 cases of ovarian
carcinoma. Another large series of 155 patients with LMD
treated from 1980 to 2002 found a median OS in solid
tumors of 2.8 months in non-breast solid tumors [29]. Only
one patient had ovarian cancer.
We found that median OS after LMD when present at
initial BM diagnosis (n = 6) was 3.55 months (95% CI,
0.69-15.8). The patients in our series who developed LMD
after a preceding BM diagnosis had no higher representa-
tion of one primary treatment modality, either surgery or
RT, prior to developing LMD. Our patient population is
different from these other large studies for several reasons.
First, LMD was primarily treated with RT in our study, in
contrast to other reports that frequently use intrathecal or
systemic chemotherapy as the principal treatment for
LMD [30,31]. In one series of 31 patients treated with
intrathecal chemotherapy, the response rate was 52% [32].
In contrast, our LMD patients treated with RT who had
follow-up imaging (n = 6) demonstrated 100% overall re-
sponse rate (both complete and partial response) as seen
on their first follow-up MRI. Second, all patients had
LMD diagnosed by MRI, with or without CSF analysis.
Lastly, our study represents a homogenous population of
one disease, as opposed to the existing series that include
one or two ovarian cancers mixed in with various other
solid tumor types. Based on the favorable responses to RT
and slightly longer survival in our series, we support
administering RT for EOC LMD. EOC is known to be a
biologically radiosensitive disease, and our results in the
setting of LMD appear to confirm this fact.
There are some limitations of our study. First, we
performed a retrospective analysis, which has its own
well-known inherent drawbacks and biases, many of
which have been outlined above. Second, not all patients
in our study had pathologic confirmation of BM from
EOC, which could theoretically have led us to include
patients with primary CNS tumors or benign disease in
this cohort. Third, because it was difficult to determine
cause of death for many patients in this retrospective ana-
lysis, we could not determine BM-specific survival, whichwould be a relevant measure of outcome in this popula-
tion. Lastly, while we were able to determine which
patients received any systemic chemotherapy before and
after RT for BM, we were unable to routinely quantify the
number of cycles of chemotherapy they received and the
specific agents with which they were treated. Prospectively
collected data on chemotherapy is required to draw strong
conclusions about the efficacy of systemic therapy in this
patient population.
Conclusions
This study is the largest reported series of patients with
EOC BM treated with modern radiation therapy. We
show that KPS less than 70, four or more BM, leptomen-
ingeal disease, and uncontrolled primary tumor predict
for inferior survival after radiation therapy for EOC BM.
A single BM is the most common presentation, occurring
in 47% of patients, and is associated with longer survival
when treated with SRS or surgery + RT. Advanced-stage
EOC is associated with shorter median interval to BM.
Over half of patients with long-term follow-up will recur
in the CNS, but can be salvaged effectively with RT or sur-
gery. LMD is associated with poor survival and occurs in
20% of our patients. RT can result in partial or complete
response of LMD, although patients will likely recur or
progress.
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